.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,320,048

« Back to Dashboard

Details for Patent: 6,320,048

Title: 3-piperidinyl-1,2-benzisoxazoles
Abstract:There is disclosed a process for preparing an enantiomeric form of the compound having the formula: ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein said process comprises the steps of: (a) reacting a racemic mixture of said compound with a chiral acid or acid chloride selected from the group consisting of tartaric acid, malic acid, mandelic acid, camphor sulfonic acid, 4,5-dihydro-1H-2-benzopyran-2-carboxylic acid, and the acid chlorides thereof, to form a mixture of diastereomeric salts or esters; (b) physically separating said mixture of diastereomeric salts or esters by selective crystallization or chromatography; and (c) converting said separated diastereomeric salts or esters into the corresponding enantiomeric forms of said compound by hydrolysis in an acidic or basic aqueous medium.
Inventor(s): Janssen; Cornelus Gerardus Maria (Vosselaar, BE), Knaeps; Alfonsus Guilielmus (Herentals, BE), Kennis; Ludo Edmond Josephine (Turnhout, BE), Vandenberk; Jan (Beerse, BE)
Assignee: Janssen Pharmaceutica, N.V. (Beerse, BE)
Filing Date:Aug 03, 1993
Application Number:08/100,907
Claims:1. A process for preparing an enantiomeric form of the compound having the formula: ##STR16##

or a pharmaceutically acceptable acid addition salt thereof,

wherein said process comprises the steps of:

(a) reacting a racemic mixture of said compound with chiral 4,5-dihydro-1H-2-benzopyran-2-carboxylic acid or the acid chloride thereof, to form a mixture of diastereomeric esters;

(b) physically separating said mixture of diastereomeric esters by chromatography; and

(c) converting said separated diastereomeric salts or esters into the corresponding enantiomeric forms of said compound by hydrolysis in an acidic or basic aqueous medium.

2. The process of claim 1 wherein the enantiomeric form of said compound recovered is (+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9- tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.

3. The process of claim 1 wherein the enantiomeric form of said compound recovered is (-)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9- tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one.

4. A process for preparing an enantiomeric form of the compound having the formula: ##STR17##

or a pharmaceutically acceptable acid addition salt thereof,

wherein said process comprises the steps of:

(a) reacting a racemic mixture of said compound with a chiral acid or acid chloride selected from the group consisting of tartaric acid, malic acid, mandelic acid, camphor sulfonic acid, 4,5-dihydro-1H-2-benzopyran-2-carboxylic acid, and the acid chlorides thereof, to form a mixture of diastereomeric salts or esters;

(b) physically separating said mixture of diastereomeric salts or esters by selective crystallization or chromatography; and

(c) converting said separated diastereomeric salts or esters into the corresponding enantiomeric forms of said compound by hydrolysis in an acidic or basic aqueous medium.

5. The process of claim 4 wherein the enantiomeric form of said compound recovered is (+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9- tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.

6. The process of claim 4 wherein the enantiomeric form of said compound recovered is (-)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9- tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc